

Curriculum Vitae Olga Nigro

LAVORO

11 Novembre 2021 - oggi

Pediatria Oncologica, Fondazione IRCCS Istituto Nazionale dei Tumori, Milano

ISTRUZIONE

Novembre 2021

Diploma di Specializzazione in Oncologia Medica, Università degli Studi di Pavia (70/70 con lode)
(30 Novembre 2020 – 31 Ottobre 2021 Periodo di Formazione presso Pediatria Oncologica, IRCCS Istituto Nazionale dei Tumori, Milano)

Febbraio 2016

Abilitazione alla professione Medica (270/270) e iscrizione all'Ordine dei Medici Chirurghi e Odontoiatri di Milano (Nr. iscrizione 44323, data iscrizione 15/02/2016)

Luglio 2015

Laurea Medicina e Chirurgia (110/110 con lode),
Università Vita-Salute San Raffaele, Milano (MI) Tesi di
Laurea in **Oncologia**

2008

1° anno presso la Facoltà di Scienze Biologiche,
Università degli Studi Roma Tre, Roma (RM)

Giugno 2008

Diploma di maturità scientifica (100/100 con lode)
Liceo Scientifico Alfonso Gatto, Agropoli (SA)

ASSOCIAZIONI DI APPARTENENZA

- ESMO (European Society of Medical Oncology)
- MASCC (Multinational Association of Supportive Care in Cancer)
- SICP (Società Italiana di Cure Palliative)
- AIEOP (Associazione Italiana Emato-Oncologia Pediatrica)
- SIOPE (European Society for Paediatric Oncology)

PUBBLICAZIONI

1. **Relapse after nonmetastatic rhabdomyosarcoma: Salvage rates and prognostic variables**
Bergamaschi L, ..., **Nigro O**, et al.
Pediatr Blood Cancer. 2022 Oct 10;e30050. doi: 10.1002/pbc.30050. Online ahead of print.
2. **Metastatic basal cell carcinoma to the bone: A case of bone metastasis in uncommon sites**
Nigro O, et al.
Dermatol Reports. 2022 Jul 12;14(3):9267. doi: 10.4081/dr.2022.9267. eCollection 2022 Sep 14.
3. **Relapsing pediatric non-rhabdomyosarcoma soft tissue sarcomas: The impact of routine imaging surveillance on early detection and post-relapse survival**
Morosi C, ..., **Nigro O**, et al.
Eur J Cancer. 2022 Nov;175:274-281. doi: 10.1016/j.ejca.2022.08.028. Epub 2022 Sep 26.

4. **Ultra Short Course Chemotherapy for Early-Stage Non-Hodgkin's Lymphoma in Children**
Schiavello E, ..., **Nigro O**, et al.
Children (Basel) 2022 Aug 25;9(9):1279. doi: 10.3390/children9091279.
5. **How ten-years of reirradiation for paediatric high-grade glioma may shed light on first line treatment**
Massimino M, ..., **Nigro O**, et al.
J Neurooncol 2022 Sep;159(2):437-445. doi: 10.1007/s11060-022-04079-4
6. **Metastatic rhabdomyosarcoma: Evidence of the impact of radiotherapy on survival. A retrospective single-center experience**
Ferrari A, ..., **Nigro O**, ..., Massimino M.
Pediatric Blood cancer 2022 Nov;69(11):e29853. doi: 10.1002/pbc.29853.
7. **Adult-type non-rhabdomyosarcoma soft tissue sarcomas in pediatric age: Salvage rates and prognostic factors after relapse**
Chiaravalli S, ..., **Nigro O**, et al.
Eur J Cancer. 2022 May 13;169:179-187. doi: 10.1016/j.ejca.2022.03.037. Online ahead of print.
8. **Caring for children with cancer evacuated from Ukraine.**
Massimino M, ..., **Nigro O**, et al.
Lancet Child Adolesc Health. 2022 Jun;6(6):365-366. doi: 10.1016/S2352-4642(22)00125-0. Epub 2022 Apr 14.
9. **Managing Care during the COVID-19 Pandemic: The Point of View and Fears of Pediatric Cancer Patients' Families.**
Nigro O, et al.
Children (Basel). 2022 Apr 13;9(4):554. doi: 10.3390/children9040554.
10. **Trabectedin-irinotecan, a potentially promising combination in relapsed desmoplastic small round cell tumor: report of two cases.**
Ferrari A, ..., **Nigro O**, et al.
J Chemother. 2022 Apr 26;1-5. doi: 10.1080/1120009X.2022.2067706. Online ahead of print.
11. **High familial burden of cancer correlates with improved outcome from immunotherapy in patients with NSCLC independent of somatic DNA damage response gene status.**
Cortellini A, ..., **Nigro O**, et al.
Hematol Oncol. 2022 Jan 21;15(1):9. doi: 10.1186/s13045-022-01226-2.
12. **Extraosseous Ewing sarcoma in children and adolescents: A retrospective series from a referral pediatric oncology center.**
Livellara V, ..., **Nigro O**, et al.
Pediatr Blood Cancer. 2021 Dec 28;e29512. doi: 10.1002/pbc.29512.
13. **A multicenter study of skin toxicity management in patients with left-sided, RAS/BRAF wild-type metastatic colorectal cancer treated with first-line anti- EGFR-based doublet regimen: is there room for improvement?**
Antonetti P, ..., **Nigro O**, et al.
Support Care Cancer. 022 Mar;30(3):2455-2465. doi: 10.1007/s00520-021-06652-5. Epub 2021 Nov 15.
14. **Post-Induction Management in Patients With Left-Sided RAS and BRAF Wild- Type Metastatic Colorectal Cancer Treated With First-Line Anti-EGFR-Base Doublet Regimens: A Multicentre Study.**
Parisi A, ..., **Nigro O**, et al.
Front Oncol. 2021 Oct 27;11:712053. doi: 10.3389/fonc.2021.712053. eCollection 2021.
15. **Recomending exercise or children with a single kidney.**
Spreafico F, Gattuso G, **Nigro O**, et al.
Nat Rev Urol. 2021 Oct 22;doi: 10.1038/s41585-021-00533-6.
16. **Langerhans cell histiocytosis in adults: a retrospective, single-center case series.**
Chiaravalli S, ..., **Nigro O**, et al.
Ann Hematol. 2021 Oct 11. doi: 10.1007/s00277-021-04694-7.
17. **PD-1/PD-L1 checkpoint inhibitors during late stages of life: an ad-hoc analysis from a large multicenter cohort.**
Santini D, Zeppola T, Russano M, ..., **Nigro O**, et al.

J Transl Med. 2021 Jun 24;19(1):270. doi: 10.1186/s12967-021-02937-9.

18. SARS-CoV-2 vaccination for adolescents and young adult patients treated at a specialist pediatric oncology unit.

Nigro O, et al.

Pediatr Blood Cancer. 2021 Oct;68(10):e29240. doi: 10.1002/pbc.29240. Epub 2021 Jul 15.

19. Prognostic role of hematologic parameters of metastatic renal cell carcinoma treated with sunitinib

Bolzacchini E, ..., Nigro O, et al.

Tumori. 2021 Jul 23;3008916211033905. doi: 10.1177/03008916211033905.

20. Clinicians' Attitude to Doublet Plus Anti-EGFR Versus Triplet Plus Bevacizumabas First-line Treatment in Left-Sided RAS and BRAF Wild-Type Metastatic Colorectal Cancer Patients: A Multicenter, "Real-Life", Case-Control Study

Parisi A, ..., Nigro O, et al.

Clin Colorectal Cancer. 2021 Jul 18;S1533-0028(21)00068-2. doi: 10.1016/j.clcc.2021.07.003.

21. Clinical outcomes of NSCLC patients experiencing early immune-related adverse events to PD-1/PD-L1 checkpoint inhibitors leading to treatment discontinuation

Russano M, Cortellini A, ..., Nigro O, et al.

Cancer Immunol Immunother. 2021 Aug 31. doi: 10.1007/s00262-021-03045-9.

22. Children and adolescent solid tumours and high-intensity end-of-life care: what can be done to reduce acute care admissions?

Podda MG, Schiavello E, ..., Nigro O, et al.

Support Palliat Care. 2021 Sep 7;bmjpscare-2021-003031.

23. Intestinal metastasis from breast cancer: Presentation, treatment and survival from a systematic literature review.

Bolzacchini E, Nigro O, Inversini D, et al.

World J Clin Oncol. 2021 May 24;12(5):382-392. doi: 10.5306/wjco.v12.i5.382.

24. Controversies on the possible role of Immune Checkpoint Inhibitors in pediatric cancers: balancing irAEs and efficacy.

Nigro O, Ferrari A, Casanova M, Orbach D, ... Massimino M.

Tumori. 2021 Aug;107(4):276-281. doi: 10.1177/03008916211010214.

25. Molecularly targeted therapy for advanced gastrointestinal noncolorectal cancer treatment: how to choose? Past, present, future.

Nigro O, Chini C, Proserpio I

Anticanc Drugs 2021 Jun 1;32(6):593-601. doi: 10.1097/CAD.0000000000001071.

26. Immune-Checkpoint Inhibitors in Platinum-Resistant Ovarian Cancer.

Indini A, Nigro O, et al.

Cancers 2021, 13, 1663. doi: 10.3390/cancers13071663.

27. Association of Obesity With Survival Outcomes in Patients With Cancer. A Systematic Review and Meta-analysis.

Petrelli F, ... Nigro O, ... Zaniboni A.

JAMA Netw Open. 2021 Mar 1;4(3):e213520. doi: 10.1001/jamanetworkopen.2021.3520.

28. Post-progression outcomes of NSCLC patients with PD-L1 expression $\geq 50\%$ receiving first-line single-agent pembrolizumab in a large multicenter real-world study.

Cortellini A, ..., Nigro O, et al.

Eur J Cancer. 2021 Mar 12;148:24-35. doi: 10.1016/j.ejca.2021.02.005.

29. The Lung Immuno-oncology Prognostic Score (LIPS-3): a prognostic classification of patients receiving first-line pembrolizumab for PD-L1 $\geq 50\%$ advanced non-small cell lung cancer.

Banna GL, ..., Nigro O, et al.

ESMO Open. 2021 Mar 15;6(2):100078. doi: 10.1016/j.esmoop.2021.100078.

30. Obesity paradox in patients with cancer: A systematic review and meta-analysis of 6,320,365 patients.

Petrelli F, Cortellini A, ..., Nigro O, et al.

BMJ. May 02, 2020. doi: 10.1101/2020.04.28.20082800.

31. **Advances in the pharmacological management of neutropenia in solid tumors: the advent of biosimilars.**
Ghidini M, Indini A, Nigro O, et al.
Expert Opin Pharmacother. 2021 Feb;1-9. doi: 10.1080/14656566.2021.1873950.
32. **Smoking status during first line immunotherapy and chemotherapy in NSCLC patients: a case-control matched analysis from a large multicenter study.**
Cortellini A, ... Nigro O, ... Porzio G.
Thorac Cancer. 2021 Feb 1. doi: 10.1111/1759-7714.13852.
33. **Complete testicular remission after chemotherapy in a patient with advanced seminoma: is the testicle a real "sanctuary"? A case report and review of the literature.**
Caspani F, Nigro O, Ogliari FR, Proserpio I, Dehò F, Capogrosso P, Valdatta L, De Palma D, Garutti L, Tamborini F, Chini C.
Anticancer Drugs 2021 Feb 15. doi: 10.1097/CAD.0000000000001042.
34. **Effect of concomitant medications with immune-modulatory properties on the outcomes of advanced cancer patients treated with immune checkpoint inhibitors: development and validation of a novel prognostic index.**
Buti S, ... Nigro O, ... Cortellini A.
Eur J Cancer. 2020 Nov 16;142:18-28. doi: 10.1016/j.ejca.2020.09.033.
35. **Integrated analysis of concomitant medications and oncological outcomes from PD-1/PD-L1 checkpoint inhibitors in clinical practice.**
Cortellini A, ... Nigro O, ... Ascierto PA.
J Immunother Cancer. 2020 Nov;8(2):e001361. doi: 10.1136/jitc-2020-001361.
36. **Baseline BMI and BMI variation during first line pembrolizumab in NSCLC patients with a PD-L1 expression $\geq 50\%$: a multicenter study with external validation.**
Cortellini A, ... Nigro O, ... Ficarella C.
Journal Immunother Cancer. 2020 Oct;8(2):e001403. doi: 10.1136/jitc-2020-001403.
37. **Letter to the Editor: considerations about recent findings on long-term adverse events of PD-1/PD-L1 checkpoint inhibitors.**
Nigro O, Cortellini A.
Eur J Cancer. 2020 Nov;139:41-42. doi: 10.1016/j.ejca.2020.08.007. Epub 2020 Sep 19.
38. **Combination of Radiation-therapy for brain metastasis and Anti-PD-1/PD-L1 Treatment in Non-small Cell Lung Cancer: two cases and review of the literature.**
Nigro O, Tuzi A, Coppola A, Tartaro T, Chini C, Pinotti G.
Anti Cancer Drug. 2021 Feb 9. doi: 10.1097/CAD.0000000000000996.
39. **An Italian retrospective survey on bone metastasis in melanoma: impact of immunotherapy and radiotherapy on survival.**
Mannavola F, Mandala M, Todisco A, ... Nigro O, ... Tucci M.
Front Oncol. 2020 Sep 15;10:1652. doi: 10.3389/fonc.2020.01652. eCollection 2020.
40. **Long-term therapy with Bevacizumab in young patient affected by NF2. Stop or continue treatment? An update of a case report and review of the literature.**
Nigro O, Coppola A, Tartaro T, Tuzi A, Vallini I, Pinotti G.
Anticancer Drugs. 2020 Aug;31(7):754-757. doi: 10.1097/CAD.0000000000000953.
41. **Immune-related Adverse Events of Pembrolizumab in a Large Real-world Cohort of Patients With NSCLC With a PD-L1 Expression $\geq 50\%$ and Their Relationship With Clinical Outcomes.**
Cortellini A, ... Nigro O, ... Cannita K.
Clin Lung Cancer. 2020 Nov;21(6):498-508.e2. doi: 10.1016/j.clcc.2020.06.010.
42. **ROS1 rearrangement in Non Small Cell Lung Cancer: where we are and where we are going to.**
Nigro O, Tuzi A, Pinotti G.
Eurasian Journal. IN PRESS. DOI: [10.14744/ejmo.2020.42771](https://doi.org/10.14744/ejmo.2020.42771)
43. **Diagnostic accuracy of contrast-enhanced spectral mammography for breast lesions: A systematic review and meta-analysis.**
Matteo Basilio Suter, Filippo Pesapane, Giorgio Maria Agazzi, Tania Gagliardi, Olga Nigro, Anna Bozzini, Francesca

Priolo, Silvia Penco, Enrico Cassano, Claudio Chini, Alessandro Squizzato.
Breast. 2020 Oct;53:8-17. doi: 10.1016/j.breast.2020.06.005.

44. Homcology: Home Chemotherapy Delivery in a Simultaneous Care Project for Frail Advanced Cancer Patients.

C Chini, L Bascialla, A Giaquinto, E Magni, SM Gobba, I Proserpio, MB Suter, **O Nigro**, G Tinelli, G Pinotti.
Support Care Cancer. 2020 Jun 13. doi: 10.1007/s00520-020-05569-9.

45. Negative impact of high body mass index on cetuximab-mediated cellular cytotoxicity against human colon carcinoma cells.

Leonardo Campiotti, Marzia Bruna Gariboldi, Lorenzo Mortara, Douglas M Noonan, Daniela Gallo, **Olga Nigro**, Elena Monti, Eliana Piantanida.
J Chemother. 2020 Jun 16;1-4. doi: 10.1080/1120009X.2020.1777722.

46. Clinicopathologic correlates of first-line pembrolizumab effectiveness in patients with advanced NSCLC and a PD-L1 expression of $\geq 50\%$.

Cortellini A, [...], **Nigro O**, [...], et al.
Cancer Immunol Immunother. 2020 Nov;69(11):2209-2221. doi: 10.1007/s00262-020-02613-9. Epub 2020 May 30.

47. Late immune-related adverse events in long-term responders to PD-1/PD- L1 checkpoint inhibitors: a multicentre study.

Nigro O, Pinotti G, De Galitiis F, et al.
Eur J Canc. 2020 Jul;134:19-28. doi: 10.1016/j.ejca.2020.04.025.

48. Precision Medicine for NSCLC in the Era of Immunotherapy: New Biomarkers to Select the Most Suitable Treatment or the Most Suitable Patient.

Rossi G, Russo A, Tagliamento M, Tuzi A, **Nigro O**, Vallome G, Sini C, Grassi M, Dal Bello MG, Coco S, Longo L, Zullo L, Tanda ET, Dellepiane C, Pronzato P, Genova C.
Cancers (Basel). 2020 Apr 30;12(5):E1125. doi: 10.3390/cancers12051125.

49. Psoriatic arthritis induced by immunotherapy and treated with Apremilast: a case report and review of the literature.

Nigro O¹, Pinotti G¹, Gueli R¹, Grigioni E¹, De Santis M², Ceribelli A², and Selmi C².
Immunotherapy. 2020 Apr 22. doi: 10.2217/imt-2019-0085.

50. Will traditional biopsy be substituted by radiomics and liquid biopsy for breast cancer diagnosis and characterisation?

Pesapane F, Suter MB, Rotili A, Penco S, **Nigro O**, Cremonesi M, Bellomi M, Jereczek-Fossa BA, Pinotti G, Cassano E.
Med Oncol. 2020 Mar 16;37(4):29. doi: 10.1007/s12032-020-01353-1

51. CDK inhibitors plus AI in first-line treatment HR-positive/HER2-negative Advanced Breast Cancer (ABC) women with or without visceral disease: time to turn page?

Nigro O¹, Marrazzo C¹, Gallerani E¹, Bascialla L¹, Gueli R¹, Grigioni E¹, De Giorgi A¹, Giaquinto A¹, Vallini I², Pinotti G¹.
Anticancer Drugs. 2020 Jun;31(5):528-532. doi: 10.1097/CAD.0000000000000904.

52. On-target Toxicities Predictive of Survival in Metastatic Renal Cell Carcinoma (mRCC) Treated With Sunitinib: A Multicenter Retrospective Study.

Bolzacchini E, Pinotti G, Bertù L, Verusio C, Galli L, Mumoli N, Barbara C, Danova M, Bregni M, Artale S, Rossini C, **Nigro O**, Antonuzzo A, Derosa L, Torchio M, Barzaghi S, Ricci I, Suter M, Ballerio A, Vallini I, Dentali F.
Clin Genitourin Cancer. 2019 Dec 5:S1558-7673(19)30307-6. doi: 10.1016/j.clgc.2019.10.003.

53. Biological effects of verbascoside and its anti-inflammatory activity on oral mucositis: a review of the literature.

Olga Nigro, Alessandro Tuzi, Tiziana Tartaro, Alice Giaquinto, Ilaria Vallini and Graziella Pinotti.
Anticancer Drugs. 2020 Jan;31(1):1-5. doi: 10.1097/CAD.0000000000000818.

54. Osimertinib beyond disease progression in T790M EGFR-positive NSCLC patients: a multicenter study of clinicians' attitudes.

Cortellini A, Leonetti A, Catino A, Pizzuttillo P, Ricciuti B, De Giglio A, Chiari R, Bordini P, Santini D, Giusti R, De Tursi M, Brocco D, Zoratto F, Rastelli F, Citarella F, Russano M, Filetti M, Marchetti P, Berardi R, Torniai M, Cortinovis D, Sala E, Maggioni C, Follador A, Macerelli M, **Nigro O**, Tuzi A, Iacono D, Migliorino MR, Banna G, Porzio G, Cannita K, Ferrara MG, Bria E, Galetta D, Ficarella C, Tiseo M.
Clin Transl Oncol. 2019 Aug 7. doi: 10.1007/s12094-019-02193-w.

55. Concomitant medications during immune checkpoint blockage in cancer patients: Novel insights in this emerging clinical scenario.

Rossi G, Pezzuto A, Sini C, Tuzi A, Citarella F, McCusker MG, **Nigro O**, Tanda E, Russo A.
Crit Rev Oncol Hematol. 2019 Oct;142:26-34. doi: 10.1016/j.critrevonc.2019.07.005.

56. Long-term therapy with bevacizumab in a young patient affected by NF-2: a casereport and review of the literature.

Olga Nigro, Tiziana Tartaro, Alessandro Tuzi, Alice Giaquinto, Matteo B. Suter and Graziella Pinotti.
Anticancer Drugs. 2019 Mar;30(3):318-321. doi: 10.1097/CAD.0000000000000732.

57. Rectovaginal fistula during treatment with axitinib in a patient with renal cell carcinoma: a case report and review of the literature.

Olga Nigro, Alessia Pastore, Tiziana Tartaro, Elena Bolzacchini, Alessandro Tuzi and Graziella Pinotti.
Anticancer Drugs. 2019 Apr;30(4):425-427. doi: 10.1097/CAD.0000000000000742.

58. Impact of neutrophils to lymphocytes ratio on major clinical outcomes in patients with acute coronary syndromes: A systematic review and meta-analysis of the literature.

Dentali F, Nigro O, Squizzato A, Gianni M, Zuretti F, Grandi AM, Guasti L.
Int J Cardiol. 2018 Sep 1;266:31-37. doi: 10.1016/j.ijcard.2018.02.116.

59. Prognostic role of neutrophils to lymphocytes ratio in patients with acute pulmonary embolism: a systematic review and meta- analysis of the literature.

Silvia Galliazzo, Olga Nigro, Lorenza Bertù, Luigina Guasti, Anna Maria Grandi, Walter Ageno, Francesco Dentali.
Intern Emerg Med. 2018 Jun;13(4):603-608. doi: 10.1007/s11739-018-1805-2.

60. Advances and challenges in the molecular biology and treatment of glioblastoma-is there any hope for the future?

Veliz I, Loo Y, Castillo O, Karachaliou N, Nigro O, Rosell R.
Ann Transl Med. 2015 Jan;3(1):7. doi: 10.3978/j.issn.2305-5839.2014.10.06.

ABSTRACT e POSTER

- **Supporto trasfusionale nel fine vita: equilibrio tra necessità clinica e alleanza terapeutica. Hospice ed istituto di cura oncologico: due realtà a confronto.**
Nigro Olga, et al.
Accettato per PRESENTAZIONE ORALE, SICP, Riccione 17-19 Novembre 2022
- **L'importanza della multidisciplinarietà: il giusto intreccio tra cure ospedaliere e cure palliative pediatriche. Esposizione di un caso clinico.**
Nigro Olga, et al.
E-PRESENTATION, SICP, Riccione 18-20 Novembre 2021
N. Abstract 118953
- **High-intensity end-of-life care in pediatric cancer patients. What can be done to reduce their admission to acute care facilities? A mono-institutional case study.**
Nigro O, et al.
PRESENTAZIONE ORALE MASCC 202, 24-26 giugno 2021, online edition
- **Family history of cancer and improved outcomes with first-line immunotherapy in NSCL patients.**
A. Cortellini, S. Buti, ..., O. Nigro, et al.
Journal of Thoracic Oncology 16 (4), S761-S762
- **Combination of Stereotactic Radiotherapy for brain metastasis and Anti-PD- 1/PD-L1 Treatment in Non-small Cell Lung Cancer.**
Nigro O, Tuzi A, Tartaro T, Pinotti G.
PRESENTAZIONE ORALE III edition YOUNG RESEARCHER IN LUNG CANCER, 9 October 2020, Brescia
- **Incidence and clinical implications of late immune-related adverse events in long responders to PD-1/PD-L1 checkpoint inhibitors: a multicentre study.**
Nigro O, et al.
POSTER Immuno BRIDGE, 4-5 December 2019, Naples POSTER ESMO-Immuno, 11-15 December 2019, Geneva (CH) Annals of Oncology (2019) 30 (suppl_11):xi16-xi32.
- **CDK inhibitors plus letrozole in first line treatment HR-positive/HER2-negative Advanced Breast Cancer (ABC) women with visceral disease: time to turn page?**
Gallerani E, Nigro O, et al.

POSTER Advanced Breast Cancer 5 (ABC5), 14-16 November 2019, Lisboa November 2019. The Breast 48:S54.

- Homcology: home chemotherapy delivery in a simultaneous care project for frail advanced cancer patients**
 Chini C, Nigro O, et al.
PRESENTAZIONE POSTER FOR ESMO 2019, 27 September-1 October, Barcelona N. Abstract 1925
Annals of Oncology (2019) 30 (suppl_11):v728-9.
- Prognostic Factors for efficacy of Ipilimumab used after AntiPD1 and/or BRAF+MEK inhibitors in Melanoma Patients: an Italian Melanoma Intergroup study.**
 Marconcini R, ..., Nigro O, et al.
PRESENTAZIONE POSTER FOR ESMO 2019, 27 September-1 October, Barcelona
 Abstract number: #4523
Annals of Oncology (2019) 30 (suppl_5):v551.
POSTER AIOM 2019, 25-27 October, Rome. N. Abstract H01
- Simultaneous Home Cares (SHC) for frail advanced cancer patients: a model of integration between no profit and Public Health System.**
Nigro O, et al.
POSTER MASCC 2019, 21-23 June 2019, San Francisco, California
N. Abstract MASCC9-0550
- First step to treat oral mucositis in cancer patients: the prevention. Effectiveness of a solution composed by verbascoside, polyvinylpyrrolidone (PVP) and sodiumhyaluronate.**
O. Nigro et al.
POSTER MASCC 2019, 21-23 Giugno 2019, San Francisco, California
N. Abstract MASCC9-0549
- CASO CLINICO. Abiraterone e ginecomastia. Lungo-sopravvivenza e beneficio sulle metastasi ossee.**
O. Nigro, et al.
POSTER TimeZone 8-9 Marzo 2019, Napoli
- Prognostic role of neutrophil to lymphocyte ratio in patients with gastric cancer.**
 C. Caprani, Bolzacchini E, O. Nigro, et al.
POSTER AIOM 2018, Roma
- Baseline predictive factors for efficacy of anti-PD1 used in first line in Melanoma patients: an Italian Melanoma Intergroup Study.**
 R. Marconcini¹, ..., O. Nigro⁴, et al
POSTER AIOM 2018 (PREMIO AIOM 2018 MELANOMA E TUMORI CUTANEI), Roma
POSTER ESMO 2018, Monaco
Annals of Oncology (2018) 29 (suppl_8):viii449.
- Evaluation of the effectiveness of a new medical device containing Verbascoside, Polyvinylpyrrolidone, and Hyaluronic Acid in prevention and treatment of mucositis in cancer patients.**
O. Nigro¹, et al.
POSTER E PRESENTAZIONE ORALE ASCO PALLIATIVE CARE 2018, San Diego, California
JCO (2018) 36 (suppl_34):206.
- Evaluation of the effectiveness of a new medical device containing verbascoside, polyvinylpyrrolidone, and hyaluronic acid in the treatment of mucositis in cancerpatients.**
O. Nigro, et al.
POSTER e PRESENTAZIONE ORALE MASCC 2018, Vienna
- Impact of neutrophils to lymphocytes ratio on major clinical outcomes in patients with acute coronary syndromes: a systematic review and meta-analysis of the literature.**

Dentali Francesco, MD, **Nigro Olga, MD**, et al.

POSTER American Heart Association 2017, Chicago

POSTER FADOI 2017, Alghero

Circulation. November 14, 2017 Vol 136, Issue suppl_1.

- **Prognostic role of neutrophil–lymphocyte ratio (NLR), platelet–lymphocyte ratio (PLR) and macrocytosis in patients affected with metastatic renal cell carcinoma (mRCC) treated by Sunitinib.**

Bolzacchini Elena¹, **Olga Nigro¹**, et al.

POSTER AIOM 2017, Roma

PREMI

- **PREMIO New-Care 2022. Idee innovative sulla Relazione Medico Paziente e di Cura, in ambito Ospedaliero e Territoriale.**

Il fumetto vuoto.

- **PREMIO in memoria della Prof.ssa Marzia Kienle (3° posto).**

Late immune-related adverse events in long-term responders to PD-1/PD-L1 checkpoint inhibitors: a multicentre study.

Nigro O, Pinotti G, De Galitiis F, et al.

Eur J Canc. 2020 Jul;134:19-28. doi: 10.1016/j.ejca.2020.04.025.

- **PREMIO AIOM 2018 MELANOMA E TUMORI CUTANEI), Roma**

Baseline predictive factors for efficacy of anti-PD1 used in first line in Melanoma patients: an Italian Melanoma Intergroup Study.

R. Marconcini¹, E. Tanda², L.A. Di Guardo³, **O. Nigro⁴**, P. Fava⁵, A. Todisco⁶, F. Morgese⁷, A. Cortellini⁸, E. Stroppa⁹, G. Galizzi¹⁰, L. Festino¹¹, E. Grego¹², S. Quadrini¹³, F. Bloise¹, A. Nuzzo¹, S. Manacorda¹, C. Orlandini¹, A. Indini², C. Astrua³, A. Falcone¹

ESPERIENZE FORMATIVE E DI RICERCA IN ITALIA E ALL'ESTERO

Novembre 2016 – Novembre 2021

- Attività di ricerca come Medico Specializzando, presso Ospedale di Circolo di Varese, Fondazione Macchi con periodi di formazione presso UO di Medicina Interna (Novembre 2016-Maggio 2017), UO di Ematologia (Dicembre 2017-Febbraio 2018), UO di Pediatria Oncologica, Ospedale Del Ponte, Varese (Marzo 2018), UO di Oncologia Medica (Novembre 2016-Novembre 2020)
- Attività di ricerca e clinica come Medico Specializzando presso Pediatria Oncologica, IRCCS Istituto Nazionale dei Tumori, Milano (30 Novembre 2020 – 31 Ottobre 2021)

Aprile 2016 – Settembre 2016

- Medico volontario presso il “**Dipartimento di Pediatria Oncologica**”, Istituto Nazionale dei Tumori, Milano (MI)

Ottobre 2015 – Marzo 2016

- Medico volontario presso il “**Dipartimento di Oncologia Medica**”, Ospedale San Raffaele, Milano (MI)

Ottobre 2013 – Luglio 2015

- Studente nel progetto di ricerca “*Evaluation of Chromogranin A and Chromogranin A fragments plasma levels in randomized proteomic stratified phase III study of second-line erlotinib versus chemotherapy in patients with advanced non-small cell lung cancer (PROSE, NCT00989690)*”, sotto la supervisione della Dr.ssa Vanesa Gregorc e del Dr. Angelo Corti

Ottobre 2012 – Luglio 2015

- Internato elettivo presso il “**Dipartimento di Oncologia Medica**”, Ospedale San Raffaele, Milano (MI), sotto la supervisione della Dr.ssa Vanesa Gregorc

Marzo 2015 – Luglio 2015

- Internato elettivo presso il “**Dipartimento di Oncologia Molecolare**”, Ospedale San Raffaele, Milano (MI), sotto la supervisione del Dr. Angelo Corti

Luglio 2014 – Settembre 2014

- Esperienza di ricerca presso l’**Istituto Oncologico Dr Rosell**, Barcellona (Spagna), sotto la supervisione del Dr. Rafael Rosell e del Dr. Santiago Viteri

CORSI FORMATIVI**Settembre 2020 – Settembre 2021**

- SUPPORTIVE CARE: THE BIG ONE

COMPETENZE LINGUISTICHE**Madrelingua italiana.**

Altre lingue:

	Scrittura	Lettura	Dialogo
Inglese	C1	C1	C1
Spagnolo	C1	C1	C2
Francese	A2	A2	A2

COMPETENZE INFORMATICHE

- Ottima conoscenza dei sistemi operativi Windows e Macintosh
- Agile utilizzo di Internet e dei motori di ricerca
- Ottima dimestichezza con l'uso di Word per l'elaborazione dei documenti e di Power Point per la creazione di presentazioni.
- Discreto uso di Excel per la creazione e modifica di fogli di calcolo
- Avvezza all' utilizzo di database bibliografici di letteratura scientifica, in particolare PubMed
- Conoscenza delle funzioni di base del programma di elaborazione statistica SPSS

La sottoscritta è a conoscenza che, ai sensi dell'art.76 DPR 28/12/2000 n.445, le dichiarazioni mendaci, la falsità negli atti e l'uso di atti falsi sono puniti ai sensi del codice penale e delle leggi speciali. Inoltre, autorizzo il trattamento dei miei dati personali ai sensi del Decreto Legislativo 30 giugno 2003, n. 196 e del GDPR (Regolamento UE 2016/679).